enicepatide (RG6640) / Roche - LARVOL DELTA

Future GLP-1 receptor co-agonists and their cardiac effects. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Agonists at glucagon-like-peptide-1 receptors (GLP-1R) are becoming approved drugs to treat not only type 2 diabetes and obesity but also cardiac diseases such as coronary heart disease, myocardial infarction and heart failure...We discuss here the known (for tirzepatide and retatrutide) or predicted contractile effects of such co-agonists on isolated cardiac preparations of experimental animals, mainly in mice and compare these results with data in isolated human cardiac preparations...We will discuss not only receptor agonists but also a receptor antagonist (AMG133). We identify research needs and controversies in the literature. We make suggestions for further preclinical research and what improvements in drug design for treatment may lie ahead."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Myocardial Infarction • Obesity • Type 2 Diabetes Mellitus

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity (Genentech Press Release) - "In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau."

P2 data • Obesity • Type 2 Diabetes Mellitus

Petrelintide Co-Administered With Enicepatide in People Living With Obesity or Overweight (ZYNERGY) (OBESITY WEEK 2026) - No abstract available

Genetic Disorders • Obesity

Effects of Enicepatide (CT-388) on Body Composition in Adults With Overweight or Obesity (OBESITY WEEK 2026) - No abstract available

Clinical • Genetic Disorders • Obesity

Changes in Cardiovascular Prognostic Markers of Central and Visceral Adiposity in Older and Younger Adults Living with Obesity/Overweight with ≥1 Weight-Related Comorbidity in a Phase 2 Trial of Enicepatide, a GLP-1/GIP Agonist (AHA 2026) - "Abstract is embargoed at this time."

Biomarker • Clinical • P2 data • Cardiovascular • Genetic Disorders • Obesity

CT-388, a GLP-1/GIP receptor agonist, reduced cardiovascular risk factors in people with overweight/obesity in a phase 2 trial (EASD 2026) - P2 | "CT-388 meaningfully reduced a broad range of well-established CV clinical risk factors (BP, lipids, CRP) in a dose-dependent manner. These findings further support the dose selection for phase 3 chronic weight management studies and suggest benefits beyond weight loss."

Clinical • P2 data • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • CRP

CT-388, a GLP-1/GIP receptor agonist, reduced vascular, haemodynamic and body fluid parameters in people with overweight/obesity in a Phase 2 trial (EASD 2026) - P2 | "CT-388 favourably modified vascular, haemodynamic, and body fluid parameters, which may be associated with a reduced risk for adverse CV events in individuals with overweight/obesity."

P2 data • Metabolic Disorders • Obesity

CT-388, a GLP-1/GIP receptor agonist, reduced CV prognostic markers of central and visceral adiposity in adults with obesity/overweight with >=1 weight-related comorbidity in a phase 2 trial (EASD 2026) - P2 | "CT-388 demonstrated reductions in prognostic CV indices associated with CA and VA, which may translate to potential CV clinical benefits."

Biomarker • Clinical • P2 data • Metabolic Disorders • Obesity

Ct-388, a camp signal-biased GLP-1/GIP receptor agonist, achieves clinically meaningful weight loss in people with overweight/obesity: results from the 48-weeks phase 2 study (EASD 2026) - P2 | "CT-388 demonstrated significant, dose-dependent WL of up to 22.7%, with a steep weight loss trajectory at W48. The safety/tolerability profile is consistent with the incretin class. These results support further development of CT-388 for the treatment of obesity and related comorbidities."

Clinical • P2 data • Metabolic Disorders • Obesity

ZYNERGY: A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight (clinicaltrials.gov) - P2 | N=486 | Not yet recruiting | Sponsor: Hoffmann-La Roche | Initiation date: Jun 2026 ➔ Sep 2026

Trial initiation date • Genetic Disorders • Obesity

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1 trial

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Hoffmann-La Roche

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study (ADA 2026) - P2 | "CT-388 demonstrated clinically meaningful, statistically significantdose-dependent WL of up to 22.7% (W48) and safety/tolerability profile consistent with the incretin class."

Clinical • Late-breaking abstract • P2 data • Metabolic Disorders • Obesity

CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study (ADA 2026) - P2 | "CT-388 demonstrated clinically meaningful, statistically significantdose-dependent WL of up to 22.7% (W48) and safety/tolerability profile consistent with the incretin class."

Clinical • Late-breaking abstract • P2 data • Metabolic Disorders • Obesity

A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option (GlobeNewswire)

New P2 trial • Obesity

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions (GlobeNewswire) - "Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity. Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity."

Late-breaking abstract • P2 data • Obesity

WC45725: A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. (clinicaltrialsregister.eu) - P2/3 | N=486 | Not yet recruiting | Sponsor: F. Hoffmann-La Roche AG

New P2/3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ZYNERGY: A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight (clinicaltrials.gov) - P2 | N=486 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P2 trial • Genetic Disorders • Obesity

BP45910: Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives (clinicaltrialsregister.eu) - P1 | N=60 | Not yet recruiting | Sponsor: F. Hoffmann-La Roche AG

New P1 trial • Obesity

WC45726: A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes (clinicaltrialsregister.eu) - P2/3 | N=273 | Not yet recruiting | Sponsor: F. Hoffmann-La Roche AG

New P2/3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Petrelintide/enicepatide (CT-388), amylin+GLP-1/GIP fixed-dose combination (GlobeNewswire) - "Zealand Pharma and Roche expect to initiate Phase 2 in the first half of 2026."

New P2 trial • Obesity

BP46585: A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity (clinicaltrialsregister.eu) - P1 | N=26 | Recruiting | Sponsor: F. Hoffmann-La Roche AG | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Enith2: A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes (clinicaltrials.gov) - P3 | N=1600 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Enith1: A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes (clinicaltrials.gov) - P3 | N=2000 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

BP46585: A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity (clinicaltrialsregister.eu) - P1 | N=26 | Not yet recruiting | Sponsor: F. Hoffmann-La Roche AG

New P1 trial • Genetic Disorders • Obesity